




Filgotinib

Revised: April 15, 2024.

CASRN: 1206161-97-8



Drug Levels and Effects

Summary of Use during Lactation

Filgotinib is not approved in the United States by the Food and Drug Administration. No information is available on the clinical use of filgotinib during breastfeeding. The European manufacturer recommends that breastfeeding be discontinued during filgotinib therapy.

Drug Levels

Filgotinib is primarily metabolized to GS-829845, an active metabolite that has about 10% the activity of filgotinib.

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Filgotinib

CAS Registry Number

1206161-97-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors